SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that CEO Greg Kunst has won one of the Healthcare Leadership awards from the Puget Sound Business Journal (PSBJ). Each year, PSBJ celebrates outstanding leaders in health care around the Puget Sound area. The Healthcare Leadership awards highlight innovative and influential thinkers whose leadership has had a lasting impact.

“This prestigious recognition from Puget Sound Business Journal really belongs to my incredibly talented team here at Aurion Biotech,” said Greg Kunst, CEO. “We are honored to receive this award, as it increases awareness of our transformational work, and our collaborative efforts to bring our cell therapy to millions of patients around the world who suffer from corneal endothelial diseases.”

Aurion Biotech is a clinical stage company developing a novel cell therapy to treat patients with corneal endothelial disease, which affects more than 16 million people throughout the world. This off-the-shelf, ready-to-use cell therapy does not require immune matching.

Aurion Biotech has acquired the intellectual property rights covering the pioneering inventions of Professor Shigeru Kinoshita, MD, Ph.D. of Kyoto Prefecture University of Medicine: cell therapy for treating corneal endothelial disease. Earlier this year, the company received regulatory approval in Japan. To date, 130 subjects have been treated in multiple completed studies involving multiple surgeons and diverse patient populations. Subjects have experienced consistent, clinically meaningful and sustained improvements in key measures of corneal health. The company launched its multi-center U.S. Phase 1/2 trial (NCT06041256) this year.

About Aurion Biotech

With offices in Seattle, Cambridge and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company’s first candidate is for the treatment of corneal edema secondary to corneal endothelial disease, and is the first off-the-shelf, clinically validated cell therapy for corneal care, having received regulatory approval in Japan. The Company has initiated clinical trials in the U.S. in 2023. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures. To learn more about Aurion Biotech, visit www.aurionbiotech.com

Contacts

Judith McGarry

(corporate communications)

415-971-2900

[email protected]

Michele Gray

(ophthalmology media)

917-449-9250

[email protected]

Beth Keshishian

(biotech & business media)

917-912-7195

[email protected]